论文部分内容阅读
目的观察沙利度胺联合VAD方案治疗多发性骨髓瘤的临床疗效及用药安全性。方法选取多发性骨髓瘤患者60例为研究对象,随机分为2组,每组30例。常规组患者给予VAD方案治疗,观察组患者应用沙利度胺联合VAD方案治疗,观察2组患者临床疗效与用药安全性。结果观察组患者临床治疗总有效率为80.0%,高于常规组的60.0%(P<0.05)。2组用药不良反应发生率比较差异均无统计学意义(P>0.05);2组患者不良反应均可耐受。结论沙利度胺联合VAD方案为临床治疗多发性骨髓瘤经济、有效、较为安全的方案,值得临床进一步推广应用。
Objective To observe the clinical efficacy and safety of thalidomide combined with VAD regimen in the treatment of multiple myeloma. Methods Sixty patients with multiple myeloma were selected as study subjects and were randomly divided into two groups (n = 30 in each group). Patients in the conventional group were given VAD regimen. Patients in the observation group were treated with thalidomide combined with VAD regimen. The clinical efficacy and safety of the two groups were observed. Results The total effective rate of clinical observation in the observation group was 80.0%, which was higher than 60.0% of the conventional group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Adverse reactions were tolerable in both groups. Conclusions Thalidomide combined with VAD regimen is an economical, effective and safe scheme for the treatment of multiple myeloma. It is worth to be further popularized and applied clinically.